Skip to main content

Rabeprazole inhibits inflammatory reaction by inhibition of cell pyroptosis in gastric epithelial cells

Abstract

Background

Helicobacter pylori (H. pylori) is a common pathogen in development of peptic ulcers with pyroptosis. Rabeprazole, a critical component of standard triple therapy, has been widely used as the first-line regimen for H. pylori infectious treatment. The aim of this study to explore the function of Rabeprazole on cell pyroptosis in vitro.

Methods

The clinical sample from patients diagnosed with or without H. pylori-infection were collected to analyze by Immunohistochemistry (IHC). Real-time quantitative PCR (qPCR), western blot (WB) and enzyme linked immunosorbent assay (Elisa) were performed to analyze the effect of Rabeprazole on cell pyroptosis, including LDH, IL-1β and IL-18.

Results

In this study, we showed that Rabeprazole regulated a phenomenon of cell pyroptosis as confirmed by lactate dehydrogenase (LDH) assay. Further results showed that Rabeprazole inhibited cell pyroptosis in gastric epithelial cells by alleviating GSDMD-executed pyroptosis, leading to decrease IL-1β and IL-18 mature and secretion, which is attributed to NLRP3 inflammasome activation inhibition. Further analysis showed that ASC, NLRP3 and Caspase-1, was significantly repressed in response to Rabeprazole stimulation, resulting in decreasing cleaved-caspase-1 expression. Most important, NLRP3 and GSDMD is significantly increased in gastric tissue of patients with H. pylori infection.

Conclusion

These findings revealed a critical role of Rabeprazole in cell pyroptosis in patients with H. pylori infection, suggesting that targeting cell pyroptosis is an alternative strategy in improving H. pylori treatment.

Peer Review reports

Background

A standard triple therapy, including the proton pump inhibitors (PPIs) and antimicrobial agents, such as amoxicillin, clarithromycin, metronidazole, and levofloxacin, is widely used as the first-line regimen for treatment of Helicobacter pylori infection [1,2,3]. Helicobacter pylori is a microbial carcinogen of gram-negative bacteria, which has been believed to be associated with the development of chronic gastritis, peptic ulcer disease, and gastric cancer (GC), leading dysfunction of inflammation [4,5,6], such as gastric mucosa-associated lymphoid tissue lymphoma (MALT) [7,8,9]. Recently, more and more attention was focused on the biological function of PPIs. We have showed that omeprazole suppressed De novo lipogenesis (DNL) in gastric cancer cells by inhibition of fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACCA) [10], while Rabeprazole was demonstrated to inhibit cell proliferation by targeting signal transducer and activator of transcription 3 (STAT3)-mediated HK2 expression [11]. Furthermore, rabeprazole has been reported to regulate DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer through CTD small phosphatase 1 (CTDSP1) [1]. However, the potential function of PPIs remained to be identified in the future work.

Cell pyroptosis, a common phenomenon between host-pathogen interactions, may lead to host cells death and release pro-inflammatory factors expression, such as IL-1β and IL-18 to aggravate inflammatory reaction [12, 13]. Inflammasomes are multiprotein complexes that activate caspase-1, leading to maturation of the proinflammatory cytokines IL-1β and IL-18 and the induction of pyroptosis [14]. In general, intracellular pathogens was recognized by the NOD-like receptors (NLPs), especially NLR family pyrin domain containing 3 (NLRP3) to form NLRP3 inflammasome activation, which further activated caspase-1 [15]. The activation of caspase-1 cleaved gasdermin D (GSDMD), IL-1β and IL-18 into mature form, enabling cell membrane pore-formation for the release of IL-1β and IL-18 and triggering of pyroptosis [16]. These stimuli, including exogenous (bacterial hemolysins, pneumolysin, etc.) and endogenous (ATP, uric acid crystals, etc.) factors, activate and prime the inflammasome [14]. In addition to pathogen or LPS stimulation, another study demonstrated that saturated fatty acids (SFAs) promoted NLRP3 inflammasome activation driven by metabolically activated macrophages through IER1a, leading to secrete IL-1β [17]. Most important, mature of SREBP-1c mediated by serials stimulation could directly activate metabolism to trigger NLRP inflammasomes activation in NK cell and macrophages [18,19,20]. These findings suggested that activation of NLRP3 inflammasomes could be triggered not only limit to host-pathogen interactions. However, the influence of Rabeprazole, an inhibitor of proton pump, in NLRP3-mediated cell pyroptosis remained unknown.

PPIs were sufficient to inhibit the gastric proton pumps by forming disulfide bonds between cysteine residues located in the luminal vestibule of the proton pumps through their acid-activated form [21], resulting in a rapid and sustained inhibition of intracellular proton efflux, as well as elevating the extracellular pH [22, 23]. In addition to our previous work showed that omeprazole suppressed De novo lipogenesis in gastric epithelial cells [10], and Rabeprazole has been demonstrated to reduce STAT3-mediated HK2 expression, leading to inhibit cell proliferation [11]. Herein, we further showed that Rabeprazole significantly decreased IL-1β and IL-18 release by inhibition of NLRP3 activation in BGC823 cells, leading to reduce caspase-1 activation. This phenomenon is attributed to the reduction of NF-KB activity caused by Rabeprazole. These finding suggested that Rabeprazole is a sufficient to alleviate inflammatory disease, targeting to cell pyroptosis by Rabeprazole could be effective to improve therapy outcome in patients.

Methods

Cell culture, treatment, reagents, and antibodies

Dulbecco’s modified eagle medium (DMEM) and fetal bovine serum (FBS) were purchased from life technologies (Kalamazoo, MI, USA). BGC823 cells were employed to be in vitro model to study the function of Rabeprazole [11]. The human gastric epithelial cell BGC823 was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in DMEM supplemented with 10% FBS. The cells were maintained at 37 °C in a humidified 5% CO2 incubator. Pierce™ BCA protein assay Kit and PageRuler™ Prestained Protein Ladder were purchased from thermo fisher, trizol was from invitrogen (Invitrogen, Thermo Fisher Scientific). All-in-one™ first-strand cDNA synthesis kit and All-in-one™ qPCR mix were from Genecopoeia™ (Rockville, MD, USA). Rabeprazole (S4845) was purchased from Selleck. LPS (BS904) was purchased from Biosharp. Other chemical reagents were from Sigma. Antibodies were purchased from Abcam: NLRP3(Abcam; ab260017, 1:2000 for WB); IL-18(Abcam; ab235697, 1:1000 for WB); IL-1β (Abcam; ab216995, 1:1000 for WB); ASC (Abcam; ab151700, 1:2000 for WB); GSDMD (Abcam; ab210070, 1:2000 for WB); Human IL-18 ELISA Kit (ab215539) and Human IL-1 β ELISA Kit (ab217608) were purchased from Abcam. β-actin (AC038) purchased from Abclonal. For treatment, BGC823 cells were stimulated for rabeprazole (10uM) for 1 h, following by LPS (500 ng/mL) treatment for further 48 h.

Real-time PCR

As described in Zhang et al. study [24], the total RNA was extracted by trizol and converted to cDNA using the All-in-one™ first-strand cDNA synthesis kit and amplified by PCR using the All-in-one™ qPCR mix according to the manufacturer’s instructions. Primer used in this study were synthesized and listed as followed: IL-1β:Forward:5′-ATGATGGCTTATTACAGTGGCAA-3′, Reverse: 5′- GTCGGAGATTCGTAGCTGGA-3′; IL-18:Forward:5′-TCTTCATTGACCAAGGAAATCGG-3′, Reverse: 5′-TCCGGGGTGCATTATCTCTAC-3′; GSDMD:Forward:5′-GTGTGTCAACCTGTCTATCAAGG-3′, Reverse: 5′-CATGGCATCGTAGAAGTGGAAG-3′; NLRP3:Forward:5′-GATCTTCGCTGCGATCAACAG-3′, Reverse: 5′-CGTGCATTATCTGAACCCCAC-3′; ASC:Forward:5′-TGGATGCTCTGTACGGGAAG-3′, Reverse: 5′-CCAGGCTGGTGTGAAACTGAA-3′; Caspase-1:Forward:5′-CCTTAATATGCAAGACTCTCAAGGA-3′, Reverse: 5′-TAAGCTGGGTTGTCCTGCACT-3′; UBC: forward, 5′-ATTTGGGTCGCGGTTCTTG-3′ and reverse, 5′-TGCCTTGACATTCTCGATGGT-3′.

Immunoblotting analysis

Immunoblotting was performed as described in our previous study [25], the whole cells were harvested and extracted in BGC823 cell after treatment, followed by SDS-PAGE. the membranes were blocked in TBST with 5% milk for 1 h and washed with PBS for 5 min. After incubation overnight with indicated primary antibodies, a secondary antibody conjugated horseradish peroxidase was added to incubate for another 1 h. the proteins were detected using an ECL reagent.

Elisa assay

IL-1β (ab229384) and IL-18(ab215539) in culture supernatants were measured and quantitated for the indicated group by ELISA according to the manufacturer’s instructions, respectively.

Relative cell death assays

LDH assay kit (abcam, ab102526) was used to analyze LDH in supernatants from BGC823 cells treated in the experiment according to the manufacturer’s instructions. Relative cell death was determined as described in Zhou et al. study [26].

Immunohistochemistry

Immunohistochemistry was performed as described in our previous work [10]. Berifly, after deparaffinization, rehydration and blocking, the sections were incubated with indicated antibody overnight at 4 °C, the slides were immersed in peroxidase-labeled secondary antibody for 30 min at room temperature. To detect the antibody-conjugated antigen reaction, the sections were incubated with 3-amino- 9-ethylcarbazole substrate-chromogen for 30 min and counterstained with hematoxylin.

Statistical analysis

GraphPad Prism V software (La Jolla, CA, USA) was applied to perform data analysis. A p less than 0.05 was considered statistical difference. Statistical differences among groups were determined by Student’s t-test, one-way ANOVA was used to determine the significance for mRNA and intensity quantified.

Results

Rabeprazole attenuated cell pyroptosis in BGC823 cells

It has been reported that disrupted glycolysis promotes pyroptosis in muscle cells by activating the NLRP3 inflammasome [27]. Our pervious study has addressed that Rabeprazole treatment in gastric epithelial cells led to a significant inhibition of hexokinase 2 (HK2)-mediated glycolysis [11], which focused us to explore the function of Rabeprazole on cell pyroptosis. LDH release assay were performed to measure in BGC823 cells treated with Rabeprazole (10uM) in a time course. As shown in the Fig. 1A, Orphologically, a smaller number of dead cells were observed in BGC823 cells treated with Rabeprazole compared with control group. LDH release assay further revealed cell death was reduced in response to Rabeprazole stimulation (Fig. 1B). these findings implied that Rabeprazole has an anti-pyroptosis effect.

Fig. 1
figure1

The effect of Rabeprazole on pyroptosis. (A) Representative images (100X) of BGC823 cells treated with or without Rabeprazole (10uM) for 48 h, magnification: 400X; (B) The LDH assay was performed to detect cell death in response to Rabeprazole treatment as indicated in various time points. Data represented the mean ± s.e.m. n = 3, t test, *p < 0.05, **p < 0.01 versus con group

Rabeprazole inhibited GSDMD activation and IL-1β and IL-18 release

The above results suggested that Rabeprazole suppressed cell pyroptosis in gastric epithelial cells. GSDMD served as a pivotal executioner [28, 29], which attracted us to identify the pyroptosis-related genes responsible for Rabeprazole treatment. Our results demonstrated that Rabeprazole treatment led to a remarkable downregulation of pro-inflammatory cytokines IL-1β and IL-18 expression by real-time PCR (Fig. 2A) and Elisa assay (Fig. 2B), which was attributed to the decreased mature GSDMD expression caused by rabeprazole stimulation in western blotting analysis (Fig. 2C). these findings suggested that Rabeprazole attenuated GSDMD-executed pyroptosis.

Fig. 2
figure2

Rabeprazole inhibited GSDMD expression, IL-1β and IL-18 release. (A) After treatment with or without rabeprazole (10uM) for 48 h, the total RNA was collected and extracted with trizol from BGC823 cells. The indicated genes were analyzed by real-time PCR assay, n = 3, t test, ***p < 0.001 versus con group; (B) BGC823 cells were treated as indicated for 48 h, and supernatant of IL-1β and IL-18 were determined by Elisa assay, data represent the mean ± s.e.m. n = 3, t test, **p < 0.01, ***p < 0.001 versus con group; (C) while the total protein of GSDMD expression, IL-1β and IL-18 were examined by western blotting, (D) the relative protein intensity was quantified and analyzed by t test, data represented the mean ± s.e.m. n = 3, ***p < 0.001 versus con group

Rabeprazole regulated pyroptosis by repressing NLRP3 inflammasome activation

NLRP3 inflammasome is currently the well-known characterized inflammasome and consists of NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), and caspase-1, which focused our attention to seek the effect of Rabeprazole on NLRP3 inflammasome. As expected, real-time PCR assay demonstrated that NLRP3 and ASC expression as well as Caspase 1 activation were drastically attenuated in BGC823 cells treated with Rabeprazole (10uM) for 72 h (Fig. 3A). In line with this, WB and quantified results also showed that Rabeprazole treatment resulted in a significant downregulation of Caspase-1 activation and NLRP3 as well as ASC at protein expression level (Fig. 3B-C). What’s more, Rabeprazole treatment significantly reversed NLRP3 inflammasomes induced by LPS (500 ng/mL) stimulation in BGC823 cells (Fig. 3D-E). These findings suggested that Rabeprazole suppressed cell pyroptosis to alleviate inflammation through repressing NLRP3 inflammasome activation in gastric epithelial cells.

Fig. 3
figure3

Rabeprazole suppressed NLRP3 inflammasomes. (A) Real-time PCR and (B) western blotting were performed to analyze NLRP3, Caspase-1 and ASC expression in BGC823 cells treated with or without rabeprazole (10uM) stimulation for 48 h, data represented the mean ± s.e.m. n = 3, t test, ***p < 0.001 versus con group, (C) the relative protein level was measured and quantified by t test, data represented the mean ± s.e.m. n = 3, ***p < 0.001 versus con group. (D) BGC823 cells were treated with rabeprazole (10uM) for 1 h, following by LPS stimulation for further 48 h as indicated, the total protein was harvested and subjected to SDS-PAGE to detect GSDMD, Cleave-IL-1β and IL-18 expression. (D) the intensity of band was quantified and analyzed by one-way ANOVA, data represented the mean ± s.e.m. n = 3, **p < 0.01, ***p < 0.001

Enrichment of inflammasome in gastric mucosa tissue

The above results showed that Rabeprazole, an PPI for H. pylori treatment, alleviated inflammation by inhibition of GSDMD-mediated pyroptosis in BGC823 of gastric cells, which attracted us to explore GSDMD expression in gastric mucosa. As shown in Table 1, a total of 36 clinical gastric mucosa samples, including 23(63.9%) boys and 13 (36.1%) girls with an age between 3 to 16 years (median age = 9), were collected from Guangzhou Women and Children’s Medical Center. The subject was divided into 14 (38.8%) H. pylori (−) control subjects and 22(61.2%) H. pylori (+) gastric tissue subjects, respectively. Detailed clinical characteristics of subjects could be available upon reasonable request, which is not public.

Table 1 the characteristic of the subjects enrolled in this study

Next, we detected NLRP3 and GSDMD expression in a set of gastric tissue diagnosed with H. pylori infection in clinic by IHC to analyze the possible changes in response to H. pylori. The results showed that GSDMD and NLRP3 expression were increased in gastric mucosa in gastric tissue with H. pylori infection (Fig. 4A-B). Taken together, these findings suggested that excessive inflammation activation and pyroptosis-related expression in the patients with Hp-infected gastric mucosa, and Rabeprazole is not only sufficient to suppress acid secretion, but also to alleviate inflammation by pyroptosis suppression.

Fig. 4
figure4

GSDMD and NLRP3 were increased in gastric mucosa with H. pylori-infectious patients. Representative images (100X) of GSDMD expression (A, left panel) and NLRP3 expression (B, left panel) in gastric mucosa sections with or without H. pylori infection, magnification: 400X; the expression of indicated protein were assessed and quantified (A-B, right panel), Data represented the mean ± s.e.m. of three independent experiments, t-test were used to analyze statistically significant, ***p < 0.001

Discussion

Rabeprazole, an inhibitor of proton pump, is sufficient to treat H. pylori infectious. However, the potential biological function of Rabeprazole is gradually to be elucidate. Previous study has revealed that omeprazole regulated lipid content in BGC823 cells, leading to reduce lipid content [10]. Recently, another work from our team demonstrated that Rabeprazole, another PPIs, suppressed STAT3-mediated glycolysis, leading to cell proliferation inhibition [11]. In this study, we further addressed Rabeprazole inhibited cell pyroptosis by destroying NLRP3 inflammasome, leading to decrease Caspase-1 activation and IL-1β and IL-18 release, and resulting in alleviating H. pylori-associated gastritis. Most important, both NLRP3 and GSDMD expression were increased in gastric cancer tissue of patients with H. pylori infectious. Taken together, these results suggested the novel function of Rabeprazole and implied a novel insight that targeting cell pyroptosis is a promising new approach to improve clinical outcome in patients with H. pylori infection.

Recently, the study has showed that Rabeprazole regulated amoebic proliferation and several functions required for parasite virulence such as cytotoxicity, oxygen reduction to hydrogen peroxide, erythrophagocytosis, proteolysis, and oxygen and complement resistances [30], also, Rabeprazole could inhibit CTD small phosphatase 1 (CTDSP1) activity, causing irinotecan resistance in colorectal cancer [31].in addition, Rabeprazole exhibits antiproliferative effects in human gastric cancer cell lines in media with various pH level [32]. However, no direct available reports about the rabeprazole in cell pyroptosis.

In our pervious study, we have demonstrated Rabeprazole suppressed HK2 expression, leading to inhibit glycolysis [11]. Interestingly, glycolysis has been reported to promote cell pyroptosis by activating the NLRP3 inflammasome [27, 33, 34]. The inflammasome NLRP3 is a molecular pathway activated by a wide range of cellular insults to elicit innate immune defenses through the activation of caspase-1 and the maturation of proinflammatory cytokines, such as IL-1βand IL-18 [35]. In line with this, our work further showed that Rabeprazole treatment led to a significant decreased IL-1β and IL-18 release, a production of cell pyroptosis. Furthermore, both NLRP3 and ASC expression are drastically reduced in response to Rabeprazole stimulation, leading to inhibit caspase-1 activation, GSDMD expression and mature IL-1β and IL-18 release. As NLRP3-mediated pyroptotic cell death and activation of Caspase-1 and GSDMD was the key event during cell pyroptosis [26], our result demonstrated that treatment of BGC823 cells with Rabeprazole remarkably decreased NLRP3/ASC/caspase-1/GSDMD expression, the core component of the inflammasome, and led to maturation and secretion of IL-1β and IL-18, suggesting that the novel function of Rabeprazole in gastric inflammation in alleviation of inflammatory reaction by the regulation of pyroptosis. However, the further work is required to elucidate whether nonclassical caspase-1-mediated pyroptosis involved in Rabeprazole regulated pyroptosis.

Interestingly, NLRP3, but not other inflammasome components, controls CD11b+ DC differentiation in the gastric LP and in other GI, lung, and lymphoid tissues in an inflammasome-independent manner, which is also required for Treg development and suppression of Th1 responses upon H. pylori infection [36], while the primary murine macrophages infected with Helicobacter pylori upregulated caspase-11 and activated caspase-1 and IL-1β secretion [37]. In this study, our results further showed that GSDMD expression, an executor of pyroptosis, is significantly increased in gastric mucosa with H. pylori infection, which is in line with the result displayed that GSDMD is drastically decreased in gastric epithelial cells in response to rabeprazole stimulation, a regimen for H. pylori-infectious treatment. What’s more, the inappropriate activation of the NLRP3 inflammasome could contribute to the onset and progression of various diseases [38], such as obesity [39], type 2 diabetes [40], inflammatory bowel disease [41], rheumatoid arthritis [42], liver fibrosis [43], Myocardial infarctions [44]. In addition to both NF-KB and SREBP-1c have been reported to regulate NLRPs transcription [17, 18, 20, 45], the further work is required to address the mechanism through which rabeprazole regulated NLRP3, leading to inhibit NLRP3 inflammasome in future work.

Conclusion

In summary, these findings extended the function of Rabeprazole and revealed a novel role of rabeprazole in the patients with H. pylori infectious, suggesting that targeting cell pyroptosis may be a novel improvement of therapeutic strategy for the patients with H. pylori.

Availability of data and materials

The datasets generated during and/or analyses during the current study are available from the corresponding author on reasonable request.

Abbreviations

ASC:

apoptosis-associated speck-like protein containing a CARD

ACCA:

acetyl-CoA carboxylase

CTDSP1:

CTD small phosphatase 1

CCND1:

Cyclin D1

DNL:

De novo lipogenesis

Elisa:

enzyme-linked immunosorbent assay

FASN:

fatty acid synthase

GC:

gastric cancer

GSH:

glutathione

GECs:

Gastric epithelial cells

GSDMD:

gasdermin D

H. pylori :

Helicobacter pylori

HK2:

Hexokinase 2

IL:

Interleukin

IHC:

Immunohistochemistry

LPS:

lipopolysaccharide

LDH:

lactate dehydrogenase

MALT:

mucosa-associated lymphoid tissue

NF-κB:

nuclear factor kappa-light-chain-enhancer of activated B cells

NLRP3:

NOD-like receptor family, pyrin domain containing 3

PPI:

Proton Pump Inhibitor

QPCR:

quantitative polymerase chain reaction

STAT3:

Signal transducer and activator of transcription 3

SFA:

saturated fatty acids

SREBP:

Sterol regulatory element-binding transcription factor 1

WB:

western blotting

References

  1. 1.

    Lee YD, Kim SE, Park SJ, Park MI, Moon W, Kim JH, et al. Efficacy of seven-day high-dose esomeprazole-based triple therapy versus seven-day standard dose non-esomeprazole-based triple therapy as the first-line treatment of patients with helicobacter pylori infection. Korean J Gastroenterol. 2020;76(3):142–9. https://doi.org/10.4166/kjg.2020.76.3.142.

    Article  PubMed  Google Scholar 

  2. 2.

    Abbass A, Khalid S, Boppana V, Hanson J, Lin H, McCarthy D. Giant gastric ulcers: an unusual culprit. Dig Dis Sci. 2020;65(10):2811–7. https://doi.org/10.1007/s10620-020-06573-z.

    Article  PubMed  Google Scholar 

  3. 3.

    Chen G, Feng P, Wang S, Ding X, Xiong J, Wu J, et al. An herbal formulation of Jiawei Xiaoyao for the treatment of functional dyspepsia: a multicenter, randomized, placebo-controlled, Clinical Trial. Clin Transl Gastroenterol. 2020;11(10):e00241. https://doi.org/10.14309/ctg.0000000000000241.

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Korotkaya Y, Shores D. Helicobacter pylori in pediatric patients. Pediatr Rev. 2020;41(11):585–92. https://doi.org/10.1542/pir.2019-0048.

    Article  PubMed  Google Scholar 

  5. 5.

    Ansari S, Yamaoka Y. Helicobacter pylori Virulence Factor Cytotoxin-Associated Gene A (CagA)-Mediated Gastric Pathogenicity. Int J Mol Sci. 2020;21(19):7430. https://doi.org/10.3390/ijms21197430.

  6. 6.

    Zhang Y, Sun J, Dong Y, Shen X, Zhang Z. Vicenin-2 inhibits the Helicobacterium pylori infection associated gastric carcinogenic events through modulation of PI3K/AKT and Nrf2 signaling in GES-1 cells. J Biochem Mol Toxicol. 2021;35(3):e22680. https://doi.org/10.1002/jbt.22680. Epub 2020 Dec 16.

  7. 7.

    Qumar S, Nguyen TH, Nahar S, Sarker N, Baker S, Bulach D, et al. A comparative whole genome analysis of Helicobacter pylori from a human dense South Asian setting. Helicobacter. 2020;21(19):7430. https://doi.org/10.3390/ijms21197430.

  8. 8.

    Sjomina O, Pavlova J, Niv Y, Leja M. Epidemiology of Helicobacter pylori infection. Helicobacter. 2018;23 Suppl 1:e12514. https://doi.org/10.1111/hel.12514.

  9. 9.

    Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010;23(4):713–39. https://doi.org/10.1128/CMR.00011-10.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Chen P, Li L, Wang H, Zhao J, Cheng Y, Xie J, et al. Omeprazole, an inhibitor of proton pump, suppresses De novo lipogenesis in gastric epithelial cells. Biomed Pharmacother. 2020;130:110472. https://doi.org/10.1016/j.biopha.2020.110472.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Zhou Y, Chen S, Yang F, Zhang Y, Xiong L, Zhao J, et al. Rabeprazole suppresses cell proliferation in gastric epithelial cells by targeting STAT3-mediated glycolysis. Biochem Pharmacol. 2021;188:114525. https://doi.org/10.1016/j.bcp.2021.114525. Epub 2021 Mar 17.

  12. 12.

    Fuchs Y, Steller H. Live to die another way: modes of programmed cell death and the signals emanating from dying cells. Nat Rev Mol Cell Biol. 2015;16(6):329–44. https://doi.org/10.1038/nrm3999.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Tang L, Lu C, Zheng G, Burgering BM. Emerging insights on the role of gasdermins in infection and inflammatory diseases. Clin Transl Immunology. 2020;9(10):e1186. https://doi.org/10.1002/cti2.1186.

    Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Franchi L, Munoz-Planillo R, Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. 2012;13(4):325–32. https://doi.org/10.1038/ni.2231.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Malireddi RKS, Kesavardhana S, Karki R, Kancharana B, Burton AR, Kanneganti TD. RIPK1 distinctly regulates Yersinia-induced inflammatory cell death, PANoptosis. Immunohorizons. 2020;4(12):789–96. https://doi.org/10.4049/immunohorizons.2000097.

  16. 16.

    Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660–5. https://doi.org/10.1038/nature15514.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Robblee MM, Kim CC, Porter Abate J, Valdearcos M, Sandlund KL, Shenoy MK, et al. Saturated fatty acids engage an IRE1alpha-dependent pathway to activate the NLRP3 Inflammasome in myeloid cells. Cell Rep. 2016;14(11):2611–23. https://doi.org/10.1016/j.celrep.2016.02.053.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Nigro D, Menotti F, Cento AS, Serpe L, Chiazza F, Dal Bello F, et al. Chronic administration of saturated fats and fructose differently affect SREBP activity resulting in different modulation of Nrf2 and Nlrp3 inflammasome pathways in mice liver. J Nutr Biochem. 2017;42:160–71. https://doi.org/10.1016/j.jnutbio.2017.01.010.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Assmann N, O'Brien KL, Donnelly RP, Dyck L, Zaiatz-Bittencourt V, Loftus RM, et al. Srebp-controlled glucose metabolism is essential for NK cell functional responses. Nat Immunol. 2017;18(11):1197–206. https://doi.org/10.1038/ni.3838.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Im SS, Yousef L, Blaschitz C, Liu JZ, Edwards RA, Young SG, et al. Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. Cell Metab. 2011;13(5):540–9. https://doi.org/10.1016/j.cmet.2011.04.001.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Roche VF. The chemically elegant proton pump inhibitors. Am J Pharm Educ. 2006;70(5):101. https://doi.org/10.5688/aj7005101.

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17(12):1507–14. https://doi.org/10.1046/j.1365-2036.2003.01496.x.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272(36):22438–46. https://doi.org/10.1074/jbc.272.36.22438.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Zhang S, Xu W, Wang H, Cao M, Li M, Zhao J, et al. Inhibition of CREB-mediated ZO-1 and activation of NF-kappaB-induced IL-6 by colonic epithelial MCT4 destroys intestinal barrier function. Cell Prolif. 2019;52(6):e12673. https://doi.org/10.1111/cpr.12673.

    Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Xu W, Zhang Z, Zou K, Cheng Y, Yang M, Chen H, et al. MiR-1 suppresses tumor cell proliferation in colorectal cancer by inhibition of Smad3-mediated tumor glycolysis. Cell Death Dis. 2017;8(5):e2761. https://doi.org/10.1038/cddis.2017.60.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Zhou L, Liu T, Huang B, Luo M, Chen Z, Zhao Z, et al. Excessive deubiquitination of NLRP3-R779C variant contributes to very-early-onset inflammatory bowel disease development. J Allergy Clin Immunol. 2021;147(1):267–79. https://doi.org/10.1016/j.jaci.2020.09.003. Epub 2020 Sep 15.

  27. 27.

    Liu D, Xiao Y, Zhou B, Gao S, Li L, Zhao L, et al. PKM2-dependent glycolysis promotes skeletal muscle cell pyroptosis by activating the NLRP3 inflammasome in dermatomyositis/polymyositis. Rheumatology (Oxford). 2021;60(5):2177–89. https://doi.org/10.1093/rheumatology/keaa473.

  28. 28.

    Poh L, Kang SW, Baik SH, Ng GYQ, She DT, Balaganapathy P, et al. Evidence that NLRC4 inflammasome mediates apoptotic and pyroptotic microglial death following ischemic stroke. Brain Behav Immun. 2019;75:34–47. https://doi.org/10.1016/j.bbi.2018.09.001.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Zhang D, Qian J, Zhang P, Li H, Shen H, Li X, et al. Gasdermin D serves as a key executioner of pyroptosis in experimental cerebral ischemia and reperfusion model both in vivo and in vitro. J Neurosci Res. 2019;97(6):645–60. https://doi.org/10.1002/jnr.24385.

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Martinez-Perez Y, Nequiz-Avendano M, Garcia-Torres I, Gudino-Zayas ME, Lopez-Velazquez G, Enriquez-Flores S, et al. Rabeprazole inhibits several functions of Entamoeba histolytica related with its virulence. Parasitol Res. 2020;119(10):3491–502. https://doi.org/10.1007/s00436-020-06868-0.

    Article  PubMed  Google Scholar 

  31. 31.

    Matsuoka H, Ando K, Swayze EJ, Unan EC, Mathew J, Hu Q, et al. CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer. PLoS One. 2020;15(8):e0228002. https://doi.org/10.1371/journal.pone.0228002.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Gu M, Zhang Y, Zhou X, Ma H, Yao H, Ji F. Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines. Oncol Lett. 2014;8(4):1739–44. https://doi.org/10.3892/ol.2014.2354.

    Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Tan LL, Jiang XL, Xu LX, Li G, Feng CX, Ding X, et al. TP53-induced glycolysis and apoptosis regulator alleviates hypoxia/ischemia-induced microglial pyroptosis and ischemic brain damage. Neural Regen Res. 2021;16(6):1037–43. https://doi.org/10.4103/1673-5374.300453.

    Article  PubMed  Google Scholar 

  34. 34.

    Jin H, Zhu Y, Wang XD, Luo EF, Li YP, Wang BL, et al. BDNF corrects NLRP3 inflammasome-induced pyroptosis and glucose metabolism reprogramming through KLF2/HK1 pathway in vascular endothelial cells. Cell Signal. 2021;78:109843. https://doi.org/10.1016/j.cellsig.2020.109843.

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Fusco R, Gugliandolo E, Biundo F, Campolo M, Di Paola R, Cuzzocrea S. Inhibition of inflammasome activation improves lung acute injury induced by carrageenan in a mouse model of pleurisy. FASEB J. 2017;31(8):3497–511. https://doi.org/10.1096/fj.201601349R.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Arnold IC, Zhang X, Urban S, Artola-Boran M, Manz MG, Ottemann KM, et al. NLRP3 controls the development of gastrointestinal CD11b(+) dendritic cells in the steady state and during chronic bacterial infection. Cell Rep. 2017;21(13):3860–72. https://doi.org/10.1016/j.celrep.2017.12.015.

    CAS  Article  PubMed  Google Scholar 

  37. 37.

    Blaser N, Backert S, Pachathundikandi SK. Immune cell signaling by helicobacter pylori: impact on gastric pathology. Adv Exp Med Biol. 2019;1149:77–106. https://doi.org/10.1007/5584_2019_360.

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Fusco R, Siracusa R, Genovese T, Cuzzocrea S, Di Paola R. Focus on the Role of NLRP3 Inflammasome in Diseases. Int J Mol Sci. 2020;21(12):4223. https://doi.org/10.3390/ijms21124223.

  39. 39.

    Kotas ME, Jurczak MJ, Annicelli C, Gillum MP, Cline GW, Shulman GI, et al. Role of caspase-1 in regulation of triglyceride metabolism. Proc Natl Acad Sci U S A. 2013;110(12):4810–5. https://doi.org/10.1073/pnas.1301996110.

    Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Ferreira NS, Bruder-Nascimento T, Pereira CA, Zanotto CZ, Prado DS, Silva JF, et al. NLRP3 Inflammasome and Mineralocorticoid Receptors Are Associated with Vascular Dysfunction in Type 2 Diabetes Mellitus. Cells. 2019;8(12):1595. https://doi.org/10.3390/cells8121595.

  41. 41.

    Villani AC, Lemire M, Fortin G, Louis E, Silverberg MS, Collette C, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet. 2009;41(1):71–6. https://doi.org/10.1038/ng.285.

    CAS  Article  PubMed  Google Scholar 

  42. 42.

    Chen L, Cao SQ, Lin ZM, He SJ, Zuo JP. NOD-like receptors in autoimmune diseases. Acta Pharmacol Sin. 2021. https://doi.org/10.1038/s41401-020-00603-2.

  43. 43.

    Longo L, Tonin Ferrari J, Rampelotto PH, Hirata Dellavia G, Pasqualotto A, PO C, et al. Gut Dysbiosis and Increased Intestinal Permeability Drive microRNAs, NLRP-3 Inflammasome and Liver Fibrosis in a Nutritional Model of Non-Alcoholic Steatohepatitis in Adult Male Sprague Dawley Rats. Clin Exp Gastroenterol. 2020;13:351–68.

    CAS  Article  Google Scholar 

  44. 44.

    Szpakowicz A, Kiliszek M, Pepinski W, Waszkiewicz E, Franaszczyk M, Skawronska M, et al. The rs12526453 polymorphism in an intron of the PHACTR1 gene and its association with 5-year mortality of patients with myocardial infarction. PLoS One. 2015;10(6):e0129820. https://doi.org/10.1371/journal.pone.0129820.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183(2):787–91. https://doi.org/10.4049/jimmunol.0901363.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank doctors in department of gastroenterology for kindly supporting.

Funding

This work was supported by National Natural Science Foundation of China [No.81770552], Natural Science Foundation of Guangdong Province [No.2017A030313838, No.2018A0303130175, No. 007115630146], Guangdong Basic and Applied Basic Research Foundation [No.2021A1515012194, No.2020A1515110109], Medical Science and Technology Foundation of Guangdong [No. A2018395], Guangzhou Municipal Science and Technology Project [No.201704020226, No.201804010148, No.201904010485, No.202102010321, No.103270671136], Guangzhou Health and Commission Program [No. 20201A011039]. Funding of Guangzhou Institute of Pediatrics/Guangzhou Women and Children’s Medical Center [No. IP-2016-005, No.IP-2018-009, GWCMC2020–1-005]. Funding of Cooperation Projects between Guangzhou Women and Children’s Medical Center and Sun Yat-Sen University (No. 201704020223), and clinical key specialty and construction of cultivating the key subject of Guangzhou Women and Children’s Medical Center (No.170000105).

Author information

Affiliations

Authors

Contributions

WFX and STG conceived and designed the experiments, JX, HC, ZHX, HLW, LLG, LF, LYX, and PYC performed experiments and analyzed data, JX, JHZ and WFX wrote the manuscript, and all authors read and approved the final manuscript.

Corresponding authors

Correspondence to Wanfu Xu or Sitang Gong.

Ethics declarations

Ethics approval and consent to participate

The study was reviewed and approved by Medical Ethics Committee for Clinical Ethical Review of Guangzhou Women and Children’s Medical Center upon the declaration of Helsinki. Written informed consent was given by the caregiver of the child for his clinical records used, which are not publicly available, however, it could be available upon request.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xie, J., Fan, L., Xiong, L. et al. Rabeprazole inhibits inflammatory reaction by inhibition of cell pyroptosis in gastric epithelial cells. BMC Pharmacol Toxicol 22, 44 (2021). https://doi.org/10.1186/s40360-021-00509-7

Download citation

Keywords

  • Rabeprazole
  • NLRP3
  • GSDMD
  • Cell pyroptosis
  • H. pylori infection